Eloxx Pharmaceuticals Inc (ELOX) - Financial and Strategic SWOT Analysis Review

Eloxx Pharmaceuticals Inc (ELOX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eloxx Pharmaceuticals Inc(Eloxx) formerly known as Sevion Therapeutics Inc, is a biopharmaceutical company that discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The company has developed protein nanocage system that allows delivery of nucleic acids and other payloads to target cells. Its product pipeline comprises SVN-001, SVN-002, SVN-003, multiple GPCR targets and ion channel. The companys SVN-002 is an antibody against an oncology target that has the potential to impact metastatic tumors, which include resistant to anti-VEGF treatments. Eloxx is headquartered in San Diego, California, the US.

Eloxx Pharmaceuticals Inc Key Recent Developments

Mar 08,2019 Eloxx Pharmaceuticals reports fourth quarter and full year 2018 financial and operating results and provides business update
Nov 08,2018 Eloxx Pharmaceuticals reports third quarter 2018 financial and operating results and provides business update
Sep 24,2018 Eloxx Pharmaceuticals To Present at the 8th Orphan Drugs & Rare Diseases Congress, the Oppenheimer Fall Summit, and the 2018 Cantor Global Healthcare Conference
Aug 07,2018 Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


List of Tables
List of Figures
Section 1 - About the Company
Eloxx Pharmaceuticals Inc - Key Facts
Eloxx Pharmaceuticals Inc - Key Employees
Eloxx Pharmaceuticals Inc - Major Products and Services
Eloxx Pharmaceuticals Inc - History
Eloxx Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Eloxx Pharmaceuticals Inc - Business Description
R&D Overview
Eloxx Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Eloxx Pharmaceuticals Inc - Strengths
Eloxx Pharmaceuticals Inc - Weaknesses
Eloxx Pharmaceuticals Inc - Opportunities
Eloxx Pharmaceuticals Inc - Threats
Eloxx Pharmaceuticals Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Eloxx Pharmaceuticals Inc, Recent Deals Summary
Section 5 Companys Recent Developments
Mar 08, 2019: Eloxx Pharmaceuticals reports fourth quarter and full year 2018 financial and operating results and provides business update
Nov 08, 2018: Eloxx Pharmaceuticals reports third quarter 2018 financial and operating results and provides business update
Sep 24, 2018: Eloxx Pharmaceuticals To Present at the 8th Orphan Drugs & Rare Diseases Congress, the Oppenheimer Fall Summit, and the 2018 Cantor Global Healthcare Conference
Aug 07, 2018: Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update
Jun 25, 2018: Eloxx Pharmaceuticals Announces Senior Management Changes
Jun 18, 2018: Eloxx Names Neil Belloff As Executive Vice President, General Counsel And Corporate Secretary
May 10, 2018: Eloxx Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results and Provides Business Update
Mar 19, 2018: Eloxx Pharmaceuticals Reports Full Year 2017 Financial and Operating Results and Provides Business Update
Feb 28, 2018: Eloxx Pharmaceuticals Appoints Biotech Leader, Dr. Jasbir Seehra, Co-founder of Acceleron Pharma, to Board of Directors
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables


Eloxx Pharmaceuticals Inc, Key Facts
Eloxx Pharmaceuticals Inc, Key Employees
Eloxx Pharmaceuticals Inc, Major Products and Services
Eloxx Pharmaceuticals Inc, History
Eloxx Pharmaceuticals Inc, Subsidiaries
Eloxx Pharmaceuticals Inc, Key Competitors
Eloxx Pharmaceuticals Inc, Ratios based on current share price
Eloxx Pharmaceuticals Inc, Annual Ratios
Eloxx Pharmaceuticals Inc, Annual Ratios (Cont...1)
Eloxx Pharmaceuticals Inc, Interim Ratios
Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Eloxx Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures


Eloxx Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Eloxx Pharmaceuticals Inc, Ratio Charts
Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Eloxx Pharmaceuticals Inc (ELOX) - Financial and Strategic SWOT Analysis Review

Eloxx Pharmaceuticals Inc (ELOX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Eloxx Pharmaceuticals Inc - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Eloxx Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Eloxx Pharmaceuticals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350 View Report

Constellation Pharmaceuticals Inc (CNST) - Financial and Strategic SWOT Analysis Review

Constellation Pharmaceuticals Inc (CNST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

EyePoint Pharmaceuticals Inc (PSDV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available